Habitat radiomics and deep learning fusion nomogram to predict EGFR mutation status in stage I non-small cell lung cancer: a multicenter study.

Journal: Scientific reports
Published Date:

Abstract

Develop a radiomics nomogram that integrates deep learning, radiomics, and clinical variables to predict epidermal growth factor receptor (EGFR) mutation status in patients with stage I non-small cell lung cancer (NSCLC). We retrospectively included 438 patients who underwent curative surgery and completed driver-gene mutation tests for stage I NSCLC from four academic medical centers. Predictive models were established by extracting and analyzing radiomic features in intratumoral, peritumoral, and habitat regions of CT images to identify EGFR mutation status in stage I NSCLC. Additionally, three deep learning models based on the intratumoral region were constructed. A nomogram was developed by integrating representative radiomic signatures, deep learning, and clinical features. Model performance was assessed by calculating the area under the receiver operating characteristic (ROC) curve. The established habitat radiomics features demonstrated encouraging performance in discriminating between EGFR mutant and wild-type, with predictive ability superior to other single models (AUC 0.886, 0.812, and 0.790 for the training, validation, and external test sets, respectively). The radiomics-based nomogram exhibited excellent performance, achieving the highest AUC values of 0.917, 0.837, and 0.809 in the training, validation, and external test sets, respectively. Decision curve analysis (DCA) indicated that the nomogram provided a higher net benefit than other radiomics models, offering valuable information for treatment.

Authors

  • Jingran Wu
    Department of Oncology, General Hospital of Northern Theater Command, Shenyang, 110840, China.
  • Hao Meng
    College of Automation, Harbin Engineering University, Harbin 150001, China.
  • Lin Zhou
    Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Biosciences and Biopharmaceutics, Guangdong Pharmaceutical University Guangzhou 510006 People's Republic of China zhoulin@gdpu.edu.cn +86-20-39352151 +86-20-39352151.
  • Meiling Wang
    School of Communications and Information Engineering, Xi'an University of Posts and Telecommunications, Xi'an, China.
  • Shanxiu Jin
    Department of Oncology, General Hospital of Northern Theater Command, Shenyang, 110840, China.
  • Hongjuan Ji
    Department of Oncology, General Hospital of Northern Theater Command, Shenyang, 110840, China.
  • Bona Liu
    Department of Oncology, General Hospital of Northern Theater Command, Shenyang, 110840, China. apbnaliu@sina.com.
  • Peng Jin
  • Cheng Du
    Department of Mechanical and Mechatronics Engineering, Waterloo Institute of Nanotechnology, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada. nzhou@uwaterloo.ca.